Free Trial
NASDAQ:INDP

Indaptus Therapeutics Q1 2026 Earnings Results & Report

Indaptus Therapeutics logo
$3.17 +0.02 (+0.63%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$3.20 +0.03 (+0.95%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Indaptus Therapeutics beat analyst earnings expectations in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$0.23 versus the -$1.87 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Indaptus Therapeutics EPS Results

Actual EPS
-$0.23
Consensus EPS
-$1.87
Beat/Miss
Beat by +$1.64
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Indaptus Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Indaptus Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules.

Indaptus Therapeutics Q1 2026 Earnings FAQ

Indaptus Therapeutics (NASDAQ:INDP) reported earnings of -$0.23 per share for Q1 2026, beating the consensus estimate of -$1.87. The report was announced on Friday, May 15, 2026.

Indaptus Therapeutics' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Indaptus Therapeutics on the company's earnings history page.

Indaptus Therapeutics Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Indaptus Therapeutics (NASDAQ:INDP) Stock Jumps 5.1% - Here's Why
See More Indaptus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Indaptus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indaptus Therapeutics and other key companies, straight to your email.

About Indaptus Therapeutics

Indaptus Therapeutics (NASDAQ:INDP) is a clinical-stage biotechnology company developing immunotherapies intended to stimulate the immune system to fight cancer and infectious diseases. Its approach uses proprietary bacterial-based candidates designed to activate multiple immune pathways.

The company’s lead candidate, Decoy20, is an investigational immunotherapy made from a mixture of inactivated, non-pathogenic bacteria. Indaptus is evaluating the candidate in clinical research for advanced solid tumors; it has not been established as a treatment for any disease.

Indaptus is focused on developing its pipeline rather than marketing approved products. The company is headquartered in the United States, and its publicly described clinical work has included U.S. research sites.

View Indaptus Therapeutics Profile